EntreMed announced that it has commenced a Phase 1 study of MKC-1 in leukemia patients.
According to Entremed, MKC-1 is a novel, orally active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multidrug resistant cell lines.
In previous studies, MKC-1 demonstrated broad antitumor effects, including tumor growth inhibition or regression in multiple preclinical models, even in paclitaxel-resistant models, the company said.
MKC-1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in during cell mitosis and induce apoptosis, the company added.
Additionally, MKC-1 showed enhanced activity with cytosine arabinoside (Ara-C) in
combination studies when added either simultaneously or sequentially in an AML cell line, according to the company.